STORM THERAPEUTICS LIMITED

• ◆

  Material uncertainty over going concern

  However, the requirement for additional funding means there is a material uncertainty about the group and the company's ability to continue as a going concern.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. STORM THERAPEUTICS LIMITED 2016-06-24 → present
2. ICENI THERAPEUTICS LIMITED 2015-04-21 → 2016-06-24

Accounting basis

IFRS

Reporting scope

Consolidated group

Abridged

Yes — abridged accounts (limited disclosure)

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“However, the requirement for additional funding means there is a material uncertainty about the group and the company's ability to continue as a going concern.”

Group structure

1. STORM THERAPEUTICS LIMITED · parent
   1. Storm Therapeutics Inc. 100% · USA · Biotechnology
   2. Storm Therapeutics GK 100% · Tokyo · Dormant

Significant events

• “During 2025, Storm's lead compound (STC-15), which is a highly selective METTL3 inhibitor, commenced a Phase 1b clinical study.”
• “On 23 January 2025, the company received £13.6 million through the completion of the first tranche of a Series C financing round.”
• “On 4 December 2025, the company received US$11.0 million through the completion of a second tranche of the Series C financing.”
• “During late 2025, Storm announced it would be closing its operations in Cambridge, UK in order to focus its resources on its clinical asset STC-15.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

10

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.